No Data
Whitehawk Therapeutics Presents Real‐World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock
Express News | WhiteHawk Therapeutics - Files to Offer and Resell up to 22.32 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: Whitehawk Therapeutics (WHWK) and Eledon Pharmaceuticals (ELDN)
Whitehawk Expands CPT113 ADC Platform Through New Option Deal